Microneedling and PRP: How Each Stimulates Regrowth
How do microneedling and platelet-rich plasma each stimulate hair regrowth at the biological level?
Both of these treatments end up in the same place, but they take opposite roads to get there. Microneedling makes your scalp produce its own growth factors by injuring it on purpose, while platelet-rich plasma skips the injury and hands the follicle a concentrated dose of those same signals directly. Knowing which road you're on matters, because it changes what your own healing capacity has to contribute.
| What's happening | Microneedling | Platelet-rich plasma |
|---|---|---|
| The trigger | Controlled injury, 0.5 to 1.5 mm in scalp work | Injected concentrate at follicle depth |
| Where growth factors come from | Your own tissue makes them in response | Platelet alpha granules, concentrated 2 to 6 times baseline |
| Cells being targeted | Dermal papilla and bulge stem cells | Dermal papilla and bulge stem cells |
| Effect on the cycle | Prolongs anagen, shortens telogen | Prolongs anagen, shortens telogen |
| Hard limit | Can't create a follicle | Can't create a follicle |
Both treatments act only on follicles that are still alive but underperforming, converging on the dermal papilla and the bulge stem cell reservoir to prolong anagen and shorten telogen, and neither one creates a new follicle.
What happens in the scalp during the wound healing cascade that microneedling sets off?
The repair starts before you've finished the pass. What makes this useful for hair isn't the wound itself but the chemical racket the damaged skin cells kick up, because those alarm signals travel sideways to the stem cells sitting a fraction of a millimetre away from each needle track. The whole conversation is short-lived, which is the reason your protocol has gaps in it instead of running continuously.
- Haemostasis, within seconds: Severed capillaries in the papillary dermis bring platelets to the site, and contact with exposed collagen triggers release of platelet derived growth factor and transforming growth factor beta.
- Inflammatory phase, hours to two days: Neutrophils arrive within hours, macrophages take over around twenty-four to forty-eight hours and switch from clearing debris to driving repair.
- The keratinocyte alarm: Disrupted skin cells dump interleukin-1 alpha, interleukin-6, interleukin-8 and tumour necrosis factor alpha into the tissue, recruiting fibroblasts and raising vascular endothelial growth factor and fibroblast growth factor 7.
- Proliferative phase, day three onward: New collagen goes down, new capillaries sprout, and the vascular plexus feeding each follicle gets denser.
- The follicle switch: Wnt ligands from the repair reach the bulge stem cells and stabilise beta-catenin, which is what tells a resting follicle to start a new growth phase.
Cytokine levels peak in the first few days and the proliferative signalling largely resolves within two to three weeks, which is why sessions are spaced anywhere from weekly to monthly instead of run back to back.
Which growth factors are concentrated in platelet-rich plasma and what do they signal?
A single platelet is a prepacked repair kit carrying fifty to eighty alpha granules stuffed with hundreds of bioactive proteins, so concentrating platelets concentrates the payload. Five of those proteins carry most of the hair-specific argument, and one of them cuts both ways.
- Platelet derived growth factor: Drives proliferation of dermal papilla cells and surrounding mesenchymal cells.
- Vascular endothelial growth factor: Builds the perifollicular capillary network that feeds a follicle in anagen.
- Insulin-like growth factor 1: Prolongs the growth phase and keeps follicle cells from shutting down.
- Transforming growth factor beta: Builds matrix, but is also implicated in pushing follicles into catagen.
Most preparation protocols aim for roughly two to six times whole-blood platelet baseline, since too dilute is indistinguishable from plasma and laboratory work shows overly concentrated preparations can inhibit rather than stimulate cell proliferation.
How does the hair follicle growth cycle determine whether a treatment can restore hair?
Everything either treatment can or can't do for you is decided by the cycle, not by the technique. Your follicles run a loop, and pattern loss works by shortening the productive part of that loop a little more each time around. That's why the calendar for judging results is measured in months rather than weeks.
- Anagen, two to seven years: The follicle actively builds a hair shaft, and about eighty-five to ninety percent of your scalp sits here at any moment.
- Catagen, two to three weeks: The follicle regresses and production stops.
- Telogen, roughly three months: The follicle rests, then sheds the old shaft and starts over.
- Miniaturisation: Dihydrotestosterone shortens each successive anagen in sensitive follicles, so every cycle produces a shorter, finer, paler shaft.
- The dividing line: A miniaturised follicle still has its papilla and bulge cells and can be pushed back; a unit replaced by a fibrous streamer has nothing left to stimulate.
A new anagen hair grows at roughly one centimetre a month against a cycle measured in years, so three months is too soon to judge anything, six months is the earliest fair assessment, and twelve months is where the real answer lives.
Why is the dermal papilla the biological target both treatments are aiming at?
Think of the dermal papilla as the follicle's control board rather than part of its machinery. The matrix cells that physically build your hair shaft are among the fastest-dividing cells in your body, but they only divide on instruction, and the papilla is what issues it. Hit the control board and you change the output; miss it and you've treated the wrong part.
- Shaft diameter tracks papilla size: A terminal follicle sits on several thousand papilla cells, a miniaturised one on a fraction of that.
- It's where androgens act: Papilla cells carry the androgen receptors and the 5-alpha reductase that converts testosterone to dihydrotestosterone.
- It runs the anagen switch: Wnt/beta-catenin signalling and the return instructions to the matrix both originate here.
- It talks to the bulge: Papilla signals call stem cell progeny downward at the start of every cycle.
Shaft diameter tracks dermal papilla cell number almost proportionally, and laboratory work showing that platelet concentrate increases papilla cell proliferation and upregulates beta-catenin is the strongest mechanistic evidence either treatment has.
Do the two treatments act through the same signalling pathways or different ones?
Same endpoint, different entry point, and that distinction isn't academic. One supplies no biological material at all and makes your tissue manufacture everything; the other supplies the material and barely injures you. Where they overlap tells you why combining them is an interesting question rather than an obvious win.
| Pathway or effect | Microneedling | Platelet-rich plasma |
|---|---|---|
| Vascular endothelial growth factor, beta-catenin, anagen extension | Yes, via repair response | Yes, via delivered payload |
| Keratinocyte interleukin signalling and mechanotransduction | Yes | No |
| Dermal matrix remodelling | Yes | Minimal |
| Precise dosing at follicle depth | No, relies on diffusion | Yes |
| Depends on your own healing capacity | Entirely | Less so, but platelet quality still counts |
Both treatments raise vascular endothelial growth factor and platelet derived growth factor, stabilise beta-catenin and extend anagen, but microneedling adds keratinocyte signalling and matrix remodelling that injection doesn't, while injection places concentrations a wound response alone can't generate.
How does needle depth change the biological response in the scalp?
Depth decides which tissue you injure, and that decides which biology answers. Going too shallow is the more common mistake and it produces nothing but exfoliation; going too deep buys you bleeding and inflammation without buying you more growth.
The follicular bulge stem cell reservoir sits at approximately 1 to 1.5 millimetres, which is why scalp needling for hair is commonly set between 0.5 and 1.5 millimetres, while sub-0.3 millimetre passes never reach it at all.
Does microneedling work partly by helping topical medication reach the follicle?
Yes, and it's arguably the best-evidenced thing needling does for hair, which is a little awkward since it's the mechanism people talk about least. Your stratum corneum is an extremely effective barrier, and only a low single-digit percentage of a typical topical scalp solution ever reaches the dermis. Needling punches thousands of temporary conduits straight through it, and that window doesn't stay open long.
Impedance measurements in human subjects put micropore lifetime at roughly two to three days and longer in darker skin, and a randomised comparison found men receiving needling plus topical minoxidil substantially outperformed minoxidil alone on hair count at twelve weeks.
What do scalp biopsies and follicle counts show after each treatment?
Photographs show what you notice; histology shows whether the follicle actually changed. A four millimetre punch biopsy sectioned horizontally lets a pathologist count follicular units, separate terminal from vellus hairs and spot the fibrous streamers that mark permanent loss, though most trials use non-invasive trichoscopy instead. The direction of the findings is reasonably consistent, but the quality of the evidence is where you should keep your attention.
- Density gains: Randomised and half-head studies report roughly twenty to thirty more hairs per square centimetre over three to six months against saline-injected control sides.
- Shaft diameter: Pooled changes have not reached statistical significance.
- Tissue-level changes: Biopsy studies report increased follicle number, thicker epithelium, markedly increased perifollicular vascularity, upregulated beta-catenin and higher Ki-67 proliferation markers in bulge cells.
- The weaknesses: Sample sizes frequently under fifty, follow-up rarely past six to twelve months, blinding is difficult, and preparation protocols differ so much that pooling results is questionable.
Randomised and half-head studies have generally reported hair density increases in the region of twenty to thirty hairs per square centimetre over three to six months relative to saline-injected control sides, while pooled shaft diameter changes have not reached statistical significance.
Which biological conditions make a follicle unable to respond to either stimulus?
Here's the hard limit, stated plainly: neither treatment creates a follicle, so where there's no living follicle there's no possible response. Some of what blocks a response is permanent, some of it is actively dangerous to treat, and some of it is fixable first. Telling those three apart is exactly why a diagnosis has to come before a treatment decision.
A smooth, shiny scalp with no visible follicular openings means the units are gone rather than shrunken, and once a follicle has been replaced by fibrous tissue neither treatment can restore it.
How long does the biological effect last once the treatment course stops?
Neither treatment changes why you were losing hair in the first place. Pattern loss is a progressive, genetically set response to dihydrotestosterone, and both of these act downstream of it, pushing follicles toward growth while the pressure driving them the other way carries on unchanged. That one fact governs everything about how long your results last and what keeping them costs.
- The stimulus is brief: The wound healing cascade resolves within two to three weeks and injected growth factors are consumed or degraded within days.
- What persists is the follicles, not the signal: Once those follicles finish the cycle you moved them into, they revert to whatever the underlying condition dictates.
- Initial course: Typically three or four sessions about a month apart to build the effect.
- Indefinite maintenance: Sessions every few months, though the review literature is clear that ideal session count and spacing haven't been established.
- When maintenance stops: Reported experience is that density drifts back toward baseline over the following months, and the early warning is increased shedding with thinning shaft diameter at the crown or hairline.
Because both treatments act downstream of the dihydrotestosterone driving the loss, gains fade back toward baseline over the months after maintenance stops, making maintenance two or three times a year a multi-thousand dollar commitment across five years rather than a one-off course.
